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A modular synthesis of functionalised phenols 
enabled by controlled boron speciation  
John J. Molloy,a Robert P. Law,a,b James W. B. Fyfe,a Ciaran P. Seath,a David J. 
Hirst,b and Allan J. B. Watsona  
A modular synthesis of functionalised biaryl phenols from two boronic acid derivatives has 
been developed via one-pot Suzuki-Miyaura cross-coupling, chemoselective control of 
boron solution speciation to generate a reactive boronic ester in situ, and oxidation. The 
utility of this method has been further demonstrated by application in the synthesis of drug 
molecules and components of organic electronics, as well as within iterative cross-coupling. 
 
Introduction 
The main text of the article should go here with headings as 
appropriate. The biaryl phenol moiety is a privileged structure 
that has found wide-ranging applications within the 
pharmaceutical, agrochemical, and material industries (Figure 
1a).1 For example, the basic biaryl phenol skeleton represents 
the principle architecture of (i) the breast cancer treatment 
raloxifene2 and the non-steroidal anti-inflammatory drug 
(NSAID) diflunisal,3 (ii) the fungicide bitertanol,4 and (iii) 
components of the E7 liquid crystal blend.5 Biaryl phenols are 
also of continued interest within academic research, particularly 
in total synthesis where many structurally unique natural 
products, such as (+)-Cavicularin6 and Biphenomycin A,7 
feature this motif.  
 Of the methods available for the synthesis of biaryl phenols, 
Suzuki-Miyaura cross-coupling8 of, for example, halophenols 
with boronic acid derivatives is perhaps the most direct method. 
However, many of these processes can be problematic, with 
diminished yields due to issues with boronate formation from 
the free phenol.9 Use of a protected phenol or suitable latent 
hydroxyl may therefore be preferable in these cases. 
 We considered a novel approach towards the synthesis of 
biaryl phenols using two boron species in which a reactive 
boronic ester takes part in a Suzuki-Miyaura cross-coupling to 
establish the required C-C bond and a protected boronic ester 
acts as a latent hydroxyl unit (Figure 1b).10 We have previously 
demonstrated the formal homologation of aryl boronic acid 
pinacol esters (BPin) using boronic acid N-methyliminodiacetic 
acid (BMIDA) esters11 via chemoselective control of boron 
solution speciation.12 This method provides a one step synthesis 
of a new reactive BPin ester primed for further reaction, such as 
further Suzuki-Miyaura cross-coupling, while avoiding 
ancillary deprotection and isolation steps. Herein we show how 
this controlled speciation process can be smoothly coupled to 
an oxidative event providing a one-pot, step-efficient, modular 
synthesis of functionalised biaryl phenols. 
 
 
 
Figure 1. (a) Importance of biaryl phenols. (b) A modular 
biaryl phenol synthesis enabled by chemoselective boron 
speciation. 
 
Results and discussion 
To probe the appropriateness of controlled speciation in this 
context, we established the reactivity of aryl BPin and BMIDA 
esters towards oxidation using oxidants known to be effective for 
similar transformations (Table 1). BPin esters are very labile towards 
oxidation10 while BMIDA esters have previously been shown to 
withstand common neutral or acidic oxidative conditions such as 
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Swern, TPAP/NMO, and DMP oxidations as well as the 
comparatively harsh Jones oxidation.13 However, tolerance of 
oxidation in basic media was anticipated to be low as BMIDA esters 
are readily hydrolysed to liberate the readily oxidisable parent 
boronic acid.14 As expected, biphenyl BPin 1, with available p 
orbital, was efficiently oxidized with peroxide (entries 1 and 3), 
however, little oxidation was observed with Oxone¨, NaOCl, or 
NaBO3 (entries 5, 7, and 9). BMIDA 2 was surprisingly inert, even 
under basic reaction conditions and with the more nucleophilic 
peroxide oxidants due to the occupied p orbital (entries 2, 4, 6, 8, 
and 10). A small quantity of oxidation is observed if there is 
sufficient hydrolysis of the BMIDA to the parent oxidatively labile 
boronic acid (e.g., entry 2). These results further demonstrate the 
remarkable resilience of BMIDA esters towards oxidation as well as 
confirm the requirement for use of a more reactive boronic ester in 
the designed process. 
 
Table 1. Selection and optimisation of oxidant. 
 
Entry Boronic ester Oxidant 3a (%)a 
1 1 30% aq. H2O2 98 
2 2 30% aq. H2O2 10 
3 1 UHPb 87 
4 2 UHPb 2 
5 1 sat. aq. Oxone¨ 9 
6 2 sat. aq. Oxone¨ Ð 
7 1 NaOCl Ð 
8 2 NaOCl Ð 
9 1 NaBO34H2O 18 
10 2 NaBO34H2O 1 
a Determined by HPLC analysis using an internal standard.15 b UHP 
= urea-hydrogen peroxide. 
 
With chemoselective boronic ester oxidation demonstrated, we 
sought to generate a one-pot protocol for the synthesis of biaryl 
phenols (Scheme 1). PhBPin (4) was reacted with haloaryl BMIDA 
5 under conditions that promote chemoselective generation of a 
reactive BPin intermediate (6). Subsequent one-pot treatment with 
H2O2 generated the desired phenolic product 3a in 80% isolated 
yield. 
 
 
Scheme 1. Modular biaryl phenol synthesis enabled by 
chemoselective boron speciation. 
 
Having identified effective conditions for the modular phenol 
synthesis, we sought to ascertain the generality of our protocol 
through application to a diverse range of BPin and BMIDA 
components (Figure 2). A library of functionalised phenolic products 
was rapidly prepared from commercial building blocks and with 
typically high levels of synthetic efficiency, especially for BMIDA 
units with electron-withdrawing functionality. For those reactions in 
which the cross-coupling was found to be slow, use of a more active 
catalyst system (Pd(OAc)2/SPhos) was beneficial. In addition to the 
formation of biaryl phenols (3a-r), the synthesis of styrenyl phenols 
was similarly effective (3s-w). 
 
 
Figure 2. Scope of the modular phenol synthesis. Yields are isolated 
yields of pure products. a Using Pd(OAc)2 (4 mol%) and SPhos (8 
mol%) as the catalyst. 
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In addition to the chemoselectivity control with regards to boron, 
this procedure also exhibits remarkable chemoselectivity for 
common functionality.16 The mildly basic reaction conditions 
preclude oxidations that proceed via an electrophilic H2O2 
mechanism. Consequently, the in situ generated biaryl BPin 
intermediate is chemoselectively oxidised in the presence of 
oxidatively labile functionality including olefinic moieties such as 
styrenes (3s-u, w) and stilbenes (3v), electron-rich heterocycles such 
as furans (3f, 3o), and heteroatoms such as sp2-nitrogen (3c, 3d, 3j, 
3n, 3r) and sulfur (3b, 3i, 3k). This latter aspect enables preparation 
of the biaryl phenolic core of raloxifene (3k).2 In addition, the 
reaction tolerates functional groups that are potentially labile via a 
nucleophilic H2O2 mechanism, such as esters and ketones (3h, 3l). 
To further demonstrate the synthetic utility of our method, we 
have applied this protocol towards the preparation of commercialised 
products and within iterative synthesis (Scheme 2).  
 
 
Scheme 2. (a) Synthesis of diflunisal 7. (b) Synthesis of E7 
cyanobiphenyl 8. (c) Synthesis of triaryl phenol 9 via one-pot 
iterative cross-coupling and oxidation. 
 
Diflunisal3,17 7 was prepared in 50% overall yield over two 
steps (Scheme 2a). The yield-limiting issue of this process was 
found to be the in situ generation of a protodeboronation-prone 
boronic acid intermediate.18 Additionally, 8, a component of the 
E7 liquid crystal blend,5 was isolated in 80% yield with no 
reaction observed at the oxidatively labile nitrile functionality 
(Scheme 2b). Furthermore, high levels of chemoselective 
control can be achieved in a one-pot iterative cross-coupling11,19 
with three different boron species (Scheme 2c). Synthesis of the 
triaryl phenol 9 involves the formation of two C-C bonds, 
recycling of pinacol over multiple boron species, and 
chemoselective oxidation to provide the desired triaryl phenol 
product in 91% isolated yield. 
Conclusions 
In summary, chemoselective control of boron solution 
speciation provides expedient access to oxidatively labile 
pinacol boronic esters, which enables a modular, iterative 
synthesis of phenolic frameworks. The reaction is tolerant of a 
diverse range of useful functionality: pH control renders 
electrophilic oxidations inactive while the mild reaction 
conditions prevent nucleophilic oxidation of any functionality 
other than BPin. This approach is highly applicable as shown 
through the preparation of commercialised drug molecules and 
materials as well as within iterative cross-coupling processes. 
This study further demonstrates the utility of speciation control 
as a method for chemoselective bond formation. 
 
Experimental Section 
Materials and methods  
Purification of starting materials. All reagents and solvents 
were obtained from commercial suppliers and were used 
without further purification unless otherwise stated. Purification 
was carried out according to standard laboratory methods.20 
Dry THF was obtained from a PureSolv SPS-400-5 solvent 
purification system. This solvent was transferred to and stored 
in a septum-sealed oven-dried flask over previously activated 4 
 molecular sieves and purged with and stored under N2. 
CH2Cl2, Et2O, EtOAc, MeCN, and petroleum ether 40-60¡ for 
purification purposes were used as obtained from suppliers 
without further purification. K3PO4 was dried in a Heraeus 
Vacutherm oven at 60 ¡C under vacuum for a minimum of 24 
hours before use.  
Experimental details. Reactions were carried out using 
conventional glassware (preparation of intermediates) or in 
capped 5 mL microwave vials (optimisation reactions and 
reactions for Table 1, Scheme 1, Figure 2, and Scheme 2). The 
glassware was oven-dried (150 ¡C) and purged with N2 before 
use. Purging refers to a vacuum/nitrogen-refilling procedure. 
Room temperature was generally 18 ¡C. Reactions were carried 
out at elevated temperatures using a temperature-regulated 
hotplate/stirrer.  
Purification of products. Thin layer chromatography was 
carried out using Merck silica plates coated with fluorescent 
indicator UV254. These were analysed under 254 nm UV light 
or developed using potassium permanganate solution. Normal 
phase flash chromatography was carried out using ZEOprep 60 
HYD 40-63 µm silica gel. Reverse phase flash chromatography 
was carried out using IST Isolute C18 cartridges.  
Analysis. Fourier Transformed Infra-Red (FTIR) spectra were 
obtained on a Shimadzu IRAffinity-1 machine. 19F NMR 
spectra were obtained on a Bruker AV 400 spectrometer at 376 
MHz. 11B NMR spectra were obtained on a Bruker AV 400 
spectrometer at 128 MHz. 1H and 13C, NMR spectra were 
obtained on either a Bruker AV 400 at 400 MHz and 101 MHz, 
respectively, or Bruker DRX 500 at 500 MHz and 126 MHz, 
respectively. Chemical shifts are reported in ppm and coupling 
constants are reported in Hz: CDCl3 is referenced at 7.26 (
1H) 
and 77.0 (13C), DMSO-d6 referenced at 2.50 (1H) and 39.5 
(13C), and CD3CN referenced at 1.94 (
1H) and 118.3, 1.3 (13C). 
High-resolution mass spectra were obtained through analysis at 
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the EPSRC UK National Mass Spectrometry Facility at 
Swansea University. Reversed phase HPLC data was obtained 
on an Agilent 1200 series HPLC using a Machery-Nagel 
Nucleodur C18 column, which was maintained at a constant 
temperature of 40 ¡C. Analysis was performed using a gradient 
method, eluting with 5 Ð 80% MeCN/H2O over 16 minutes at a 
flow rate of 2 mL/min. Samples for HPLC analysis were 
prepared through the addition of 2 mL of caffeine standard (to 
the completed reaction mixture, the resulting solution was then 
stirred before the removal of a 200 µL aliquot. The aliquot was 
diluted to 1 mL with MeCN, a 200 µL aliquot of the diluted 
solution was then filtered through cotton wool and further 
diluted with 800 µL MeCN and 500 µL H2O for HPLC analysis 
against established conversion factors. 
Synthetic procedures 
General procedure A. For example, synthesis of compound 3a. 
To an oven-dried 5 mL microwave vial was added 4-
bromophenylboronic acid MIDA ester (70.6 mg, 0.226 mmol, 1 
equiv), 4,4,5,5-tetramethyl-2-phenyl-1,3,2-dioxaborolane (69.3 mg, 
0.339 mmol, 1.5 equiv), Pd(dppf)Cl2·DCM (7.4 mg, 0.009 mmol, 4 
mol%), and K3PO4 (144 mg, 0.678 mmol, 3 equiv). The vial was 
then capped and purged with N2 before addition of THF (0.9 mL, 
0.25 M) and H2O (20 µL, 1.13 mmol, 5 equiv). The reaction mixture 
was then heated to 90 ¡C in a sand bath for 24 h. The reaction 
mixture was allowed to cool to room temperature then decapped, 
cooled to 0 ûC, and 30% wt. aq. H2O2 (177 µL, 2.26 mmol, 10 equiv) 
was added dropwise. The reaction mixture was then stirred at room 
temperature for 3 h. The reaction mixture was then cooled to 0 ûC 
and quenched with sodium metabisulphite (176 mg, 0.904 mmol, 4 
equiv) before being concentrated under vacuum. The residue was 
then dissolved in EtOAc (10 mL) and washed with sat. aq. NH4Cl 
(2x10 mL) and brine (10 mL). The aqueous washings were re-
extracted with EtOAc (10 mL), the combined organics were filtered 
through a hydrophobic frit packed with Celite¨, and concentrated 
under vacuum before being purified by column chromatography 
(C18 silica gel, 0-60% H2O in MeCN) to afford the title compound 
as a white solid (31 mg, 80%). 
General procedure B. For example, synthesis of compound 
3b. To an oven dried 5 mL microwave vial was added 3-bromo-
5-(trifluoromethyl)phenylboronic acid MIDA ester (86 mg, 
0.226 mmol, 1 equiv), benzo[b]thiophen-2-yl)-4,4,5,5-
tetramethyl-1,3,2-dioxaborolane (88.2 mg, 0.339 mmol, 1.5 
equiv), Pd(OAc)2 (2 mg, 0.009 mmol, 4 mol%), SPhos (7.4 mg, 
0.018 mmol, 8 mol%), and K3PO4 (144 mg, 0.678 mmol, 3 
equiv). The vial was then capped and purged with N2 before 
addition of THF (0.9 mL, 0.25 M) and H2O (20 µL, 1.13 mmol, 
5 equiv). The reaction mixture was then heated to 90 ¡C in a 
sand bath for 24 h. The reaction mixture was allowed to cool to 
room temperature then decapped, cooled to 0 ûC, and 30% wt. 
aq. H2O2 (177 µL, 2.26 mmol, 10 equiv) was added dropwise. 
The reaction mixture was then stirred at room temperature for 3 
h. The reaction mixture was then cooled to 0 ûC and quenched 
with sodium metabisulphite (176 mg, 0.904 mmol, 4 equiv) 
before being concentrated under vacuum. The residue was then 
dissolved in EtOAc (10 mL) and washed with sat. aq. NH4Cl 
(2x10 mL) and brine (10 mL). The aqueous washings were re-
extracted with EtOAc (10 mL), the combined organics filtered 
through a hydrophobic frit packed with Celite¨, and 
concentrated under vacuum before being purified by column 
chromatography (silica gel, 0-30% Et2O in petroleum ether) to 
afford the title compound as an orange solid (58 mg, 88%). 
Characterisation data 
The main text of the article should go here with headings as 
appropriate. 
3a: [1,1'-biphenyl]-4-ol. Prepared according to General 
Procedure A using  4-bromophenylboronic acid MIDA ester 
(70.6 mg, 0.226 mmol, 1 equiv), 4,4,5,5-tetramethyl-2-phenyl-
1,3,2-dioxaborolane (69.3 mg, 0.339 mmol, 1.5 equiv), 
Pd(dppf)Cl2·DCM (7.4 mg, 0.009 mmol, 4 mol%), K3PO4 (144 
mg, 0.678 mmol, 3 equiv), THF (0.9 mL, 0.25 M), H2O (20 µL, 
1.13 mmol, 5 equiv) and 30% wt. aq. H2O2 (177 µL, 2.26 
mmol, 10 equiv). After 27 h, the reaction mixture was subjected 
to the purification outlined in the General Procedure (C18 silica 
gel, 0-60% H2O in MeCN) to afford the title compound as a 
white solid (31 mg, 80%). υmax (solid): 3399, 3098, 3062, 1597, 
1485 cm-1. 1H NMR (CD3CN, 500 MHz): δ 7.56-7.59 (m, 2H), 
7.48-7.51 (m, 2H), 7.42 (t, J = 8.2 Hz, 2H), 7.30 (tt, J = 8.0, 2.0 
Hz, 1H), 6.99 (s, 1H), 6.89 (d, J = 8.3 Hz, 2H). 13C NMR 
(DMSO-d6, 126 MHz): δ 157.1, 140.2, 130.9, 128.7, 127.7, 
126.3, 125.9, 115.8. HRMS: exact mass calculated for [M-H]- 
(C12H9O) requires m/z 169.0659, found m/z 169.0658. 
3b: 3-(Benzo[b]thiophen-2-yl)-5-(trifluoromethyl)phenol. 
Prepared according to General Procedure B using 3-bromo-5-
(trifluoromethyl)phenylboronic acid MIDA ester (86 mg, 0.226 
mmol, 1 equiv), benzo[b]thiophen-2-yl)-4,4,5,5-tetramethyl-
1,3,2-dioxaborolane (88.2 mg, 0.339 mmol, 1.5 equiv), 
Pd(OAc)2 (2 mg, 0.01 mmol, 4 mol%), SPhos (7.4 mg, 0.02 
mmol, 8 mol%), K3PO4 (144 mg, 0.678 mmol, 3 equiv), THF 
(0.9 mL, 0.25 M), H2O (20 µL, 1.13 mmol, 5 equiv) and 30% 
wt. aq. H2O2 (177 µL, 2.26 mmol, 10 equiv). After 27 h, the 
reaction mixture was subjected to the purification outlined in 
the General Procedure (silica gel, 0-30% Et2O in petroleum 
ether) to afford the title compound as an orange solid (58 mg, 
88%). υmax (solid): 3305, 3067, 3052, 2923, 1610, 1450, 1439, 
1351, 1327 cm-1. 1H NMR (CD3CN, 500 MHz): δ 7.93 (d, J = 
7.5 Hz, 1H), 7.86 (dd, J = 6.9, 1.6 Hz, 1H), 7.77 (s, 1H), 7.64 
(s, 1H), 7.56 (s, 1H), 7.37-7.46 (m, 3H), 7.10 (s, 1H). 13C NMR 
(CD3CN, 126 MHz): δ 157.9, 141.9, 140.5, 139.4, 136.6, 132.2 
(d, 2JC-F = 32.4 Hz), 132.1 (d, 
2
JC-F = 32.4 Hz), 125.2, 125.0, 
124.0, 123.9 (d, 1JC-F = 271.8 Hz) 122.3, 121.4, 116.6, 114.3 (d, 
3
JC-F = 3.2 Hz) 111.9 (d, 
3
JC-F = 3.2 Hz). 
19F NMR (CD3CN, 
376 MHz): δ Ð64.2 (s, 3F). HRMS: exact mass calculated for 
[M-H]- (C15H8F3OS) requires m/z 293.0253, found m/z 
293.0245. 
3c: 4-(3,5-Dimethylisoxazol-4-yl)phenol. Prepared according to 
General Procedure A using 4-bromophenylboronic acid MIDA 
ester (70.6 mg, 0.226 mmol, 1 equiv), 3,5-dimethyl-4-(4,4,5,5-
tetramethyl-1,3,2-dioxaborolan-2-yl)isoxazole (75.6 mg, 0.339 
Journal Name  ARTICLE 
This journal is © The Royal Society of Chemistry 2012  J. Name., 2012, 00, 1‐3 | 5  
mmol, 1.5 equiv), Pd(dppf)Cl2·DCM (7.4 mg, 0.009 mmol, 4 
mol%), K3PO4 (144 mg, 0.678 mmol, 3 equiv), THF (0.9 mL, 
0.25 M), H2O (20 µL, 1.13 mmol, 5 equiv), and 30% wt. aq. 
H2O2 (177 µL, 2.26 mmol, 10 equiv). After 27 h, the reaction 
mixture was subjected to the purification outlined in the 
General Procedure (silica gel, 0-30% Et2O in petroleum ether) 
to afford the title compound as a white solid (37 mg, 87%). υmax 
(solid): 3194, 3025, 2926, 1612, 1591, 1424 cm-1. 1H NMR 
(CD3CN, 500 MHz): δ 7.18 (d, J = 8.8 Hz, 2H), 7.05 (br. s., 
1H), 6.90 (d, J = 8.8 Hz, 2H), 2.35 (s, 3H), 2.20 (s, 3H). 13C 
NMR (CDCl3, 126 MHz): δ 165.0, 158.9, 155.6, 130.4, 122.3, 
116.4, 115.8, 11.5, 10.7. HRMS: exact mass calculated for 
[M+H]+ (C11H12NO2) requires m/z 190.0863, found m/z 
190.0861. 
3d: 5-(1,5-Dimethyl-1H-pyrazol-4-yl)-2-methoxyphenol. 
Prepared according to General Procedure B using 5-bromo-2-
methoxyphenylboronic acid MIDA ester (85 mg, 0.25 mmol, 1 
equiv), 1,5-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-
2-yl)-1H-pyrazole (83 mg, 0.375 mmol, 1.5 equiv), Pd(OAc)2 
(2.3 mg, 0.01 mmol, 4 mol%), SPhos (8.2 mg, 0.02 mmol, 8 
mol%), K3PO4 (159 mg, 0.75 mmol, 3 equiv), THF (1 mL, 0.25 
M), H2O (22.5 µL, 1.25 mmol, 5 equiv), and 30% wt. aq. H2O2 
(195 µL, 2.5 mmol, 10 equiv). After 27 h, the reaction mixture 
was subjected to the purification outlined in the General 
Procedure (silica gel, 20-70% EtOAc in petroleum ether) to 
afford the desired product as a white solid (42 mg, 77%). υmax 
(film): 3341, 3204, 2920, 2851, 1464, 1034 cm-1. 1H NMR 
(CDCl3, 400 MHz): δ 7.53 (s, 1H), 6.96 (d, J = 2.0 Hz, 1H), 
6.91 (d, J = 8.2 Hz, 1H), 6.85 (dd, J = 8.2, 2.0 Hz, 1H), 3.93 (s, 
3H), 3.86 (s, 3H), 2.38 (s, 3H). 13C NMR (CDCl3, 101 MHz): δ 
145.3, 144.9, 136.4, 134.5, 126.8, 120.1, 118.9, 113.8, 110.6, 
55.6, 35.9, 9.8. HRMS: exact mass calculated for [M+H]+ 
(C12H15N2O2) requires m/z 219.1128, found m/z 219.1126. 
3e: 3-Fluoro-4'-(trifluoromethoxy)-[1,1'-biphenyl]-4-ol. 
Prepared according to General Procedure A using 4-bromo-2-
fluorophenylboronic acid MIDA ester (82.5 mg, 0.25 mmol, 1 
equiv), 4,4,5,5-tetramethyl-2-(4-(trifluoromethoxy)phenyl)-
1,3,2-dioxaborolane (86 mg, 0.375 mmol, 1.5 equiv), 
Pd(dppf)Cl2·DCM (8.2 mg, 0.01 mmol, 4 mol%), K3PO4 (159 
mg, 0.75 mmol, 3 equiv), THF (1 mL, 0.25 M), H2O (22.5 µL, 
1.25 mmol, 5 equiv), and 30% wt. aq. H2O2 (195 µL, 2.5 mmol, 
10 equiv). After 27 h, the reaction mixture was subjected to the 
purification outlined in the General Procedure (silica gel, 0-
10% EtOAc in petroleum ether) to afford the title compound as 
a white solid (58 mg, 85%). υmax (film): 3395, 1503, 1256, 
1200, 1159, 1117 cm-1. 1H NMR (CDCl3, 400 MHz): δ 7.50-
7.58 (m, 2H), 7.23-7.35 (m, 4H), 7.10 (t, J = 8.5 Hz, 1H), 5.23 
(br. s., 1H). 13C NMR (CDCl3, 101 MHz): δ 151.2 (d, 
1
JC-F = 
237.0 Hz), 148.6, 143.3 (d, 2JC-F = 14.6 Hz), 138.5, 133.1 (d, 
3
JC-F = 5.9 Hz), 128.0, 123.4 (d, 
3
JC-F = 5.9 Hz), 121.3, 120.5 (q, 
1
JC-F = 257.5 Hz), 117.7, 114.2 (d, 
2
JC-F = 20.5 Hz). 
19F NMR 
(CDCl3, 376 MHz): δ Ð57.8 (s, 3F), Ð140.4 (s, 1F). HRMS: 
exact mass calculated for [M]+ (C13H8F4O2) requires m/z 
272.0455, found m/z 272.0459. 
3f: 3-(Furan-3-yl)phenol. Prepared according to General 
Procedure A using 3-bromophenylboronic acid MIDA ester 
(70.6 mg, 0.226 mmol, 1 equiv), 2-(furan-3-yl)-4,4,5,5-
tetramethyl-1,3,2-dioxaborolane (65.8 mg, 0.339 mmol, 1.5 
equiv), Pd(dppf)Cl2·DCM (7.4 mg, 0.009 mmol, 4 mol%), 
K3PO4 (144 mg, 0.678 mmol, 3 equiv), THF (0.9 mL, 0.25 M), 
H2O (20 µL, 1.13 mmol, 5 equiv), and 30% wt. aq. H2O2 (177 
µL, 2.26 mmol, 10 equiv). After 27 h, the reaction mixture was 
subjected to the purification outlined in the General Procedure 
(silica gel, 0-30% Et2O in petroleum ether) to afford the title 
compound as a white solid (32 mg, 87%). υmax (solid): 3477, 
3401, 3150, 3127, 1591, 1513, 1457 cm-1. 1H NMR (CDCl3, 
500 MHz): δ 7.72 (s, 1H), 7.47-7.50 (m, 1H), 7.26 (t, J = 7.9 
Hz, 1H), 7.09 (td, J = 7.8, 1.1 Hz, 1H), 6.97-6.99 (m, 1H), 6.72-
6.79 (m, 1H), 6.65-6.71 (m, 1H), 4.88 (br. s., 1H). 13C NMR 
(CDCl3, 126 MHz): δ 155.9, 143.7, 138.7, 134.1, 130.1, 126.1, 
118.6, 113.9, 112.8, 108.9. HRMS: exact mass calculated for 
[M-H]- (C10H7O2) requires m/z 159.0452, found m/z 159.0448. 
3g: 4'-(Trifluoromethoxy)-[1,1'-biphenyl]-3-ol. Prepared 
according to General Procedure A using 3-bromophenylboronic 
acid MIDA ester (70.6 mg, 0.226 mmol, 1 equiv), 4,4,5,5-
tetramethyl-2-(4-(trifluoromethoxy)phenyl)-1,3,2-
dioxaborolane (97.7 mg, 0.339 mmol, 1.5 equiv), 
Pd(dppf)Cl2·DCM (7.4 mg, 0.009 mmol, 4 mol%), K3PO4 (144 
mg, 0.678 mmol, 3 equiv), THF (0.9 mL, 0.25 M), H2O (20 µL, 
1.13 mmol, 5 equiv), and 30% wt. aq. H2O2 (177 µL, 2.26 
mmol, 10 equiv). After 27 h, the reaction mixture was subjected 
to the purification outlined in the General Procedure (C18 silica 
gel, 0-60% H2O in MeCN) to afford the title compound as a 
pale yellow solid (47 mg, 81%). υmax (solid): 3304, 3047, 2928, 
1597, 1485, 1457 cm-1. 1H NMR (CD3CN, 500 MHz): δ 7.72-
7.68 (m, 2H), 7.37 (d, J = 8.8 Hz, 2H), 7.31 (t, J = 7.9 Hz, 1H), 
7.15-7.12 (m, 1H), 7.09-7.07 (m, 2H), 6.89-6.83 (m, 1H). 13C 
NMR (CD3CN, 126 MHz): δ 157.4, 148.5, 141.0, 140.0, 130.2, 
128.6, 121.3, 120.6 (d, 1JC-F = 255.3 Hz), 118.6, 114.7, 113.8, 
29.4. 19F NMR (CD3CN, 376 MHz): δ Ð57.8 (s, 3F). HRMS: 
exact mass calculated for [M-H]- (C13H8F3O) requires m/z 
253.0482, found m/z 253.0482. 
3h: Methyl 1-(3'-hydroxy-[1,1'-biphenyl]-4-yl)cyclopropane-1-
carboxylate. Prepared according to General Procedure A using 
3-bromophenylboronic acid MIDA ester (70.6 mg, 0.226 mmol, 
1 equiv), methyl 1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-
2-yl)phenyl)cyclopropane-1-carboxylate (102.4 mg, 0.339 
mmol, 1.5 equiv), Pd(dppf)Cl2·DCM (7.4 mg, 0.009 mmol, 4 
mol%), K3PO4 (144 mg, 0.678 mmol, 3 equiv), THF (0.9 mL, 
0.25 M), H2O (20 µL, 1.13 mmol, 5 equiv), and 30% wt. aq. 
H2O2 (177 µL, 2.26 mmol, 10 equiv). After 27 h, the reaction 
mixture was subjected to the purification outlined in the 
General Procedure (silica gel, 0-30% Et2O in petroleum ether) 
to afford the title compound as a white solid (45 mg, 75%). υmax 
(solid): 3440, 3040, 2954, 2926, 2852 , 1698, 1590 cm-1. 1H 
NMR (CDCl3, 500 MHz) δ 7.51 (d, J = 8.5 Hz, 2H), 7.40 (d, J 
= 8.2 Hz, 2H), 7.27-7.32 (m, 1H), 7.15 (d, J = 7.9 Hz, 1H), 
7.01-7.07 (m, 1H), 6.80 (dd, J = 8.0, 2.5 Hz, 1H), 3.66 (s, 3H), 
1.63-1.66 (m, 2H), 1.22-1.25 (m, 2H). 13C NMR (CDCl3, 126 
MHz): δ 175.2, 155.9, 142.6, 139.6, 138.8, 130.9, 129.9, 126.9, 
119.7, 114.2, 114.0, 52.5, 28.7, 16.8. HRMS: exact mass 
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calculated for [M-H]- (C17H15O3) requires m/z 267.1027, found 
m/z 267.1019. 
3i: 3-(Thiophen-2-yl)-5-(trifluoromethyl)phenol. Prepared 
according to General Procedure B using 3-bromo-5-
(trifluoromethyl)phenylboronic acid MIDA ester (95 mg, 0.25 
mmol, 1 equiv), 4,4,5,5-tetramethyl-2-(thiophen-2-yl)-1,3,2-
dioxaborolane (79 mg, 0.375 mmol, 1.5 equiv), Pd(OAc)2 (2.3 
mg, 0.01 mmol, 4 mol%), SPhos (8.2 mg, 0.02 mmol, 8 mol%), 
K3PO4 (159 mg, 0.75 mmol, 3 equiv), THF (1 mL, 0.25 M), 
H2O (22.5 µL, 1.25 mmol, 5 equiv), and 30% wt. aq. H2O2 (195 
µL, 2.5 mmol, 10 equiv). After 27 h, the reaction mixture was 
subjected to the purification outlined in the General Procedure 
(silica gel, 0-15% Et2O in petroleum ether) to afford the title 
compound as a brown solid (53 mg, 87%). υmax (film): 3318, 
1599, 1115, 1099 cm-1. 1H NMR (CDCl3, 400 MHz): δ 7.44-
7.47 (m, 1H), 7.35-7.39 (m, 2H), 7.26 (t, J = 2.0 Hz, 1H), 7.13 
(dd, J = 5.0, 3.5 Hz, 1H), 7.00-7.03 (m, 1H), 5.16 (s, 1H). 13C 
NMR (CDCl3, 101 MHz): δ 156.2, 142.3, 136.9, 132.7 (q, 
2
JC-F 
= 33.1 Hz), 128.2, 126.0, 124.4, 123.7 (q, 1JC-F = 272.1 Hz), 
116.0, 115.3, 111.2. 19F NMR (CDCl3, 376 MHz): δ Ð62.9 (s, 
3F). HRMS: exact mass calculated for [M-H]- (C11H6F3OS) 
requires m/z 243.0097, found m/z 243.0097. 
3j: 4-(3,5-Dimethylisoxazol-4-yl)-2-fluorophenol. Prepared 
according to General Procedure A using 4-bromo-2-
fluorophenylboronic acid MIDA ester (82.5 mg, 0.25 mmol, 1 
equiv), 4,4,5,5-tetramethyl-4-(3,5-dimethylisoxazol-4-yl)-1,3,2-
dioxaborolane (84 mg, 0.375 mmol, 1.5 equiv), 
Pd(dppf)Cl2·DCM (8.2 mg, 0.01 mmol, 4 mol%), K3PO4 (159 
mg, 0.75 mmol, 3 equiv), THF (1 mL, 0.25 M), H2O (22.5 µL, 
1.25 mmol, 5 equiv), and 30% wt. aq. H2O2 (195 µL, 2.5 mmol, 
10 equiv). After 27 h, the reaction mixture was subjected to the 
purification outlined in the General Procedure (silica gel, 10-
20% Et2O in petroleum ether) to afford the title compound as a 
white solid (41 mg, 79%). υmax (film): 3075, 1460, 1410, 1308, 
1244, 1213, 1121 cm-1. 1H NMR (CDCl3, 400 MHz): δ 7.13-
7.08 (m, 1H), 7.00 (dd, J = 11.5, 2.0 Hz, 1H), 6.94 (ddd, J = 
8.0, 2.0, 1.0 Hz, 1H), 5.98 (br. s., 1H), 2.42 (s, 3H), 2.28 (s, 
3H). 13C NMR (CDCl3, 101 MHz): δ 164.8, 158.2, 150.6 (d, 
1
JC-F = 237.0 Hz), 142.8 (d, 
2
JC-F = 16.2 Hz), 125.2 (d, JC-F = 
2.7 Hz), 122.4 (d, 3JC-F = 8.1 Hz), 117.3 (d, 
3
JC-F = 5.4 Hz), 
115.9 (d, 2JC-F =18.8 Hz), 115.2, 11.0, 10.2. 
19F NMR (CDCl3, 
376 MHz): δ Ð139.3 (s, 1F). HRMS: exact mass calculated for 
[M+H]+ (C11H11FNO2) requires m/z 208.0768, found m/z 
208.0768. 
3k: 4-(Benzo[b]thiophen-2-yl)phenol. Prepared according to 
General Procedure A using 4-bromophenylboronic acid MIDA 
ester (70.6 mg, 0.226 mmol, 1 equiv), 2-(benzo[b]thiophen-2-
yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (88.2 mg, 0.339 
mmol, 1.5 equiv), Pd(dppf)Cl2·DCM (7.4 mg, 0.009 mmol, 4 
mol%), K3PO4 (144 mg, 0.678 mmol, 3 equiv), THF (0.9 mL, 
0.25 M), H2O (20 µL, 1.13 mmol, 5 equiv), and 30% wt. aq. 
H2O2 (177 µL, 2.26 mmol, 10 equiv). After 27 h, the reaction 
mixture was subjected to the purification outlined in the 
General Procedure (silica gel, 0-30% Et2O in petroleum ether) 
to afford the title compound as an off-white solid (47 mg, 
92%). υmax (solid): 3388, 3052, 3042, 2923, 1610, 1597, 1507 
cm-1. 1H NMR (DMSO-d6, 500 MHz): δ 9.78 (s, 1H), 7.91 (d, J 
= 7.9 Hz, 1H), 7.77 (d, J = 7.9 Hz, 1H), 7.63 (s, 1H), 7.57-7.61 
(m, 2H), 7.35 (dt, J = 7.5, 1.3 Hz, 1H), 7.27-7.31 (m, 1H), 6.86 
(d, J = 8.5 Hz, 2H). 13C NMR (DMSO-d6, 126 MHz): δ 158.5, 
144.3, 141.2, 138.5, 128.0, 125.1, 125.0, 124.5, 123.7, 122.7, 
118.3, 116.4. HRMS: exact mass calculated for [M-H]- 
(C14H9OS) requires m/z 225.0380, found m/z 225.0385. 
3l: 1-(2'-Hydroxy-[1,1'-biphenyl]-4-yl)ethanone. Prepared 
according to General Procedure A using 2-bromophenylboronic 
acid MIDA ester (92 mg, 0.25 mmol, 1 equiv), 1-(4-(4,4,5,5-
tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)ethanone (92 mg, 
0.375 mmol, 1.5 equiv), Pd(dppf)Cl2·DCM (8.2 mg, 0.01 
mmol, 4 mol%), K3PO4 (159 mg, 0.75 mmol, 3 equiv), THF (1 
mL, 0.25 M), H2O (22.5 µL, 1.25 mmol, 5 equiv), and 30% wt. 
aq. H2O2 (195 µL, 2.5 mmol, 10 equiv). After 27 h, the reaction 
mixture was subjected to the purification outlined in the 
General Procedure (silica gel, 5-20% EtOAc in petroleum 
ether) to afford the title compound as a white solid (38 mg, 
72%). υmax (film): 3285, 1667, 1479, 1277, 1190, 1179, 1155 
cm-1. 1H NMR (CDCl3, 400 MHz): δ 8.11-8.05 (m, 2H), 7.63-
7.68 (m, 2H), 7.29-7.34 (m, 2H), 7.08-6.98 (m, 2H), 2.67 (s, 
3H). 13C NMR (CDCl3, 101 MHz): δ 197.4, 152.0, 142.1, 
135.6, 129.9, 129.3, 128.9, 128.5, 126.7, 120.7, 115.8, 26.2. 
HRMS: exact mass calculated for [M+H]+ (C14H13O2) requires 
m/z 213.0910, found m/z 213.0909. 
3m: 2',4'-Difluoro-[1,1'-biphenyl]-3-ol. Prepared according to 
General Procedure A using 3-bromophenylboronic acid MIDA 
ester (78 mg, 0.25 mmol, 1 equiv), 2-(2,4-difluorophenyl)-
4,4,5,5-tetramethyl-1,3,2-dioxaborolane (90 mg, 0.375 mmol, 
1.5 equiv), Pd(dppf)Cl2·DCM (8.2 mg, 0.01 mmol, 4 mol%), 
K3PO4 (159 mg, 0.75 mmol, 3 equiv), THF (1 mL, 0.25 M), 
H2O (22.5 µL, 1.25 mmol, 5 equiv), and 30% wt. aq. H2O2 (195 
µL, 2.5 mmol, 10 equiv). After 27 h, the reaction mixture was 
subjected to the purification outlined in the General Procedure 
(silica gel, 0-10% Et2O in petroleum ether) to afford the title 
compound as a white solid (43 mg, 83%). υmax (film) 3260, 
1597, 1479, 1306, 1265, 1229, 1192, 1140, 1099 cm-1. 1H NMR 
(CDCl3, 400 MHz): δ 7.41 (td, J = 8.8, 6.5 Hz, 1H), 7.34 (t, J = 
8.0 Hz, 1H), 7.10 (dq, J = 7.6, 1.5 Hz, 1H), 7.00-7.04 (m, 1H), 
6.86-7.00 (m, 3H), 5.06 (s, 1H). 13C NMR (CDCl3, 101 MHz): 
δ 161.5 (dd, 1JC-F = 250.4 Hz,
 3
JC-F = 5.4), 159.2 (dd, 
1
JC-F = 
250.4 Hz, 3JC-F = 5.4), 155.0, 136.1, 130.9 (dd, 
3
JC-F = 6.7, 5.4 
Hz), 129.3, 124.4 (dd, 2JC-F = 18.9 Hz, JC-F = 5.4 Hz), 121.0, 
115.5, 114.3, 111.0 (dd, 2JC-F = 21.5 Hz, JC-F = 2.7 Hz), 103.9 
(dd, 2JC-F = 24.2, 26.9 Hz). 
19F NMR (CDCl3, 376 MHz): δ Ð
111.3 (d, J = 7.5 Hz, 1F), Ð113.2 (d, J = 7.5 Hz, 1F). HRMS: 
exact mass calculated for [M+H]+ (C12H9F2O) requires m/z 
207.0616, found m/z 207.0619. 
3n: 3-(1-Methyl-1H-pyrazol-4-yl)phenol. Prepared according to 
General Procedure A using 3-bromophenylboronic acid MIDA 
ester (70.6 mg, 0.226 mmol, 1 equiv), 1-methyl-4-(4,4,5,5-
tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (71.2 mg, 
0.339 mmol, 1.5 equiv), Pd(dppf)Cl2·DCM (7.4 mg, 0.009 
mmol, 4 mol%), K3PO4 (144 mg, 0.678 mmol, 3 equiv), THF 
(0.9 mL, 0.25 M), H2O (20 µL, 1.13 mmol, 5 equiv), and 30% 
wt. aq. H2O2 (177 µL, 2.26 mmol, 10 equiv). After 27 h, the 
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reaction mixture was subjected to the purification outlined in 
the General Procedure (silica gel, 20-80% Et2O in petroleum 
ether) to afford the title compound as a yellow solid (33 mg, 
83%). υmax (solid): 3107, 2926, 2855, 1616, 1569, 1588, 1374 
cm-1. 1H NMR (CD3CN, 500 MHz): δ 7.79 (s, 1H), 7.72 (s, 
1H), 7.19 (t, J = 8.0 Hz, 1H), 7.03 (td, J = 7.6, 1.4 Hz, 1H), 
6.98-6.96 (m, 1H), 6.94 (br. s., 1H), 6.74-6.61 (m, 1H), 3.87 (s, 
3H). 13C NMR (DMSO-d6, 126 MHz): δ 157.7, 135.9, 133.8, 
129.7, 127.6, 122.0, 115.9, 113.0, 111.8, 38.6. HRMS: exact 
mass calculated for [M+H]+ (C10H11N2O) requires m/z 
175.0866, found m/z 175.0864. 
3o: 2-Fluoro-4-(furan-3-yl)phenol. Prepared according to 
General Procedure A using 4-bromo-2-fluorophenylboronic 
acid MIDA ester (83 mg, 0.25 mmol, 1 equiv), 2-(furan-3-yl)-
4,4,5,5-tetramethyl-1,3,2-dioxaborolane (73 mg, 0.375 mmol, 
1.5 equiv), Pd(dppf)Cl2·DCM (8.2 mg, 0.01 mmol, 4 mol%), 
K3PO4 (159 mg, 0.75 mmol, 3 equiv), THF (1 mL, 0.25 M), 
H2O (22.5 µL, 1.25 mmol, 5 equiv), and 30% wt. aq. H2O2 (195 
µL, 2.5 mmol, 10 equiv). After 27 h, the reaction mixture was 
subjected to the purification outlined in the General Procedure 
(silica gel, 0-10% EtOAc in petroleum ether) to afford the title 
compound as off-white solid (32 mg, 72%). υmax (film): 3362, 
1520, 1497, 1279, 1250, 1231, 1155, 1117, 1086, 1049, 1016 
cm-1. 1H NMR (CDCl3, 400 MHz): δ 7.67 (dd, J = 1.4, 1.0 Hz, 
1H), 7.48 (t, J = 1.7 Hz, 1H), 7.22 (dd, J = 11.5, 2.0 Hz, 1H), 
7.18 (ddd, J = 8.4, 2.1, 1.0 Hz, 1H), 7.07-6.99 (m, 1H), 6.64 
(dd, J = 1.8, 0.9 Hz, 1H), 5.14 (br. s., 1H). 13C NMR (CDCl3, 
101 MHz): δ 150.7 (d, 1JC-F = 237.0 Hz), 143.3, 141.9 (d, 
2
JC-F 
= 13.5 Hz), 137.6, 125.4 (d, 2JC-F = 8.1 Hz), 124.9 (d, JC-F = 2.7 
Hz), 121.8 (d, 3JC-F = 5.4 Hz), 117.1, 112.6 (d, 
3
JC-F = 18.8 Hz), 
108.3. 19F NMR (CDCl3, 376 MHz): δ Ð140.7 (s, 1F). HRMS: 
exact mass calculated for [M+H]+ (C10H8FO2) requires m/z 
179.0503, found m/z 179.0502. 
3p: 3-(2,4-Difluorophenyl)-5-(trifluoromethyl)phenol. Prepared 
according to General Procedure B using 3-bromo-5-
(trifluoromethyl)phenylboronic acid MIDA ester (95 mg, 0.25 
mmol, 1 equiv), 4,4,5,5-tetramethyl-2-(2,4-difluorophenyl)-
1,3,2-dioxaborolane (90 mg, 0.375 mmol, 1.5 equiv), Pd(OAc)2 
(2.3 mg, 0.01 mmol, 4 mol%), SPhos (8.2 mg, 0.02 mmol, 8 
mol%), K3PO4 (159 mg, 0.75 mmol, 3 equiv), THF (1 mL, 0.25 
M), H2O (22.5 µL, 1.25 mmol, 5 equiv), and 30% wt. aq. H2O2 
(195 µL, 2.5 mmol, 10 equiv). After 27 h, the reaction mixture 
was subjected to the purification outlined in the General 
Procedure (silica gel, 0-20% Et2O in petroleum ether) to afford 
the title compound as a brown solid (60 mg, 88%). υmax (film): 
3331, 1607, 1364, 1271, 1121, 1103 cm-1. 1H NMR (CDCl3, 
400 MHz): δ 7.43 (td, J = 8.7, 6.3 Hz, 1H), 7.34 (s, 1H), 7.19 
(d, J = 1.5 Hz, 1H), 7.14-7.11 (m, 1H), 7.03-6.92 (m, 2H), 5.30 
(br. s, 1H). 13C NMR (CDCl3, 101 MHz): δ 162.8 (dd, 
1
JC-F = 
250.0 Hz, 3JC-F = 11.0 Hz), 159.7 (dd, 
1
JC-F = 250.0 Hz, 
3
JC-F = 
11.0 Hz), 155.8, 137.4, 132.4 (q, 2JC-F = 33.1 Hz), 131.4 (dd, 
3
JC-F = 7.5, 7.5 Hz), 123.6 (dd, 
2
JC-F = 13.5 Hz, JC-F = 5.4 Hz), 
123.7 (q, 1JC-F = 272.1 Hz), 119.3, 118.2, 111.9 (dd, 
2
JC-F = 21.5 
Hz, JC-F = 3.0 Hz), 111.7, 104.6 (dd, 
2
JC-F = 25.7, 25.7 Hz). 
19F 
NMR (CDCl3, 376 MHz): δ Ð62.8 (s, 3F), Ð109.7 (d, J = 8.0 
Hz, 1F), Ð113.1 (d, J = 8.0 Hz, 1F). HRMS: exact mass 
calculated for [M+H]+ (C13H8F5O) requires m/z 275.0490, 
found m/z 275.0490. 
3q: 3',4',5'-Trifluoro-3-methoxy-[1,1'-biphenyl]-4-ol. Prepared 
according to General Procedure B using 5-bromo-2-
methoxyphenylboronic acid MIDA ester (85 mg, 0.25 mmol, 1 
equiv), 4,4,5,5-tetramethyl-2-(3,4,5-trifluorophenyl)-1,3,2-
dioxaborolane (97 mg, 0.375 mmol, 1.5 equiv), Pd(OAc)2 (2.3 
mg, 0.01 mmol, 4 mol%), SPhos (8.2 mg, 0.02 mmol, 8 mol%), 
K3PO4 (159 mg, 0.75 mmol, 3 equiv), THF (1 mL, 0.25 M), 
H2O (22.5 µL, 1.25 mmol, 5 equiv), and 30% wt. aq. H2O2 (195 
µL, 2.5 mmol, 10 equiv). After 27 h, the reaction mixture was 
subjected to the purification outlined in the General Procedure 
(silica gel, 5-20% EtOAc in petroleum ether) to afford the title 
compound as an off-white solid (41 mg, 65%). υmax (film): 
3530, 2941, 2361, 1503, 1263, 1231, 1211, 1136, 1038, 1022 
cm-1. 1H NMR (CDCl3, 400 MHz): δ 7.17-7.12 (m, 2H), 7.10 
(d, J = 2.5 Hz, 1H), 7.01 (dd, J = 8.1, 2.5 Hz, 1H), 6.93 (d, J = 
8.1 Hz, 1H), 5.73 (br. s., 1H), 3.96 (s, 3H). 13C NMR (CDCl3, 
101 MHz): δ 151.5 (ddd, 1JC-F = 248.9 Hz, 
2
JC-F = 10.0 Hz, 
3
JC-F 
= 4.1 Hz), 147.1, 146.2, 139.0 (dt, 1JC-F = 251.1 Hz, 
2
JC-F = 15.6 
Hz), 137.1 (td, 3JC-F = 8.0 Hz, JC-F = 4.3 Hz), 131.8, 118.7, 
113.2, 111.1, 110.7 (dd, 2JC-F = 15.8 Hz, 
3
JC-F = 6.0 Hz), 56.2. 
19F NMR (CDCl3, 376 MHz): δ Ð134.5 (d, J = 20.4 Hz, 2F), Ð
163.6 (t, J = 20.4 Hz, 1F). HRMS: exact mass calculated for 
[M-H]- (C13H8F3O2) requires m/z 253.0482, found m/z 
253.0477. 
3r: 2-(1-Methyl-1H-pyrazol-4-yl)phenol. Prepared according to 
General Procedure A using 2-bromophenylboronic acid MIDA 
ester (70.6 mg, 0.226 mmol, 1 equiv), 1-methyl-4-(4,4,5,5-
tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (71.2 mg, 
0.339 mmol, 1.5 equiv), Pd(dppf)Cl2·DCM (7.4 mg, 0.009 
mmol, 4 mol%), K3PO4 (144 mg, 0.678 mmol, 3 equiv), THF 
(0.9 mL, 0.25 M), H2O (20 µL, 1.13 mmol, 5 equiv), and 30% 
wt. aq. H2O2 (177 µL, 2.26 mmol, 10 equiv). After 27 h, the 
reaction mixture was subjected to the purification outlined in 
the General Procedure (silica gel, 20-80% Et2O in petroleum 
ether) to afford the title compound as a yellow solid (30 mg, 
75%). υmax (solid): 3060, 2928, 2852, 1566, 1457, 1355 cm
-1. 
1H NMR (CD3CN, 500 MHz): δ 7.96 (s, 1H), 7.82 (s, 1H), 7.51 
(dd, J = 7.7, 1.7 Hz, 1H), 7.20 (s, 1H), 7.05-7.11 (m, 1H), 6.87-
6.93 (m, 2H), 3.89 (s, 3H). 13C NMR (CD3CN, 126 MHz): δ 
153.0, 137.3, 129.4, 127.4, 127.0, 120.2, 119.8, 118.3, 115.8, 
38.3. HRMS: exact mass calculated for [M+H]+ (C10H11N2O) 
requires m/z 175.0866, found m/z 175.0864. 
3s: 5-(3,6-Dihydro-2H-pyran-4-yl)-2-methoxyphenol. Prepared 
according to General Procedure B using (5-bromo-2-
methoxyphenyl)boronic acid MIDA ester (85 mg, 0.25 mmol, 1 
equiv), 2-(3,6-dihydro-2H-pyran-4-yl)-4,4,5,5-tetramethyl-
1,3,2-dioxaborolane (79 mg, 0.375 mmol, 1.5 equiv), Pd(OAc)2 
(2.3 mg, 0.01 mmol, 4 mol%), SPhos (8.2 mg, 0.02 mmol, 8 
mol%), K3PO4 (159 mg, 0.75 mmol, 3 equiv), THF (1 mL, 0.25 
M), H2O (22.5 µL, 1.25 mmol, 5 equiv), and 30% wt. aq. H2O2 
(195 µL, 2.5 mmol, 10 equiv). After 27 h, the reaction mixture 
was subjected to the purification outlined in the General 
Procedure (silica gel, 10-20% EtOAc in petroleum ether) to 
afford the title compound as an off-white solid (35 mg, 67%). 
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υmax (film): 3302, 2916, 1510, 1276, 1118, 1028, 1014 cm
-1. 1H 
NMR (CDCl3, 400 MHz): δ 7.00 (d, J = 2.2 Hz, 1H), 6.89 (dd, J 
= 8.4, 2.2 Hz, 1H), 6.82 (d, J = 8.4 Hz, 1H), 6.03 (tt, J = 3.0, 
1.5 Hz, 1H), 5.60 (br. s, 1H), 4.31 (q, J = 2.8 Hz, 2H), 3.92 (t, J 
= 5.5 Hz, 2H), 3.89 (s, 3H), 2.45-2.50 (m, 2H). 13C NMR 
(CDCl3, 101 MHz): δ 145.5, 145.0, 133.5, 132.9, 120.6, 115.9, 
110.6, 109.9, 65.4, 64.0, 55.5, 26.7. HRMS: exact mass 
calculated for [M+H]+ (C12H15O3) requires m/z 207.1016, found 
m/z 207.1012. 
3t: 3-Fluoro-2',3',4',5'-tetrahydro-[1,1'-biphenyl]-4-ol. Prepared 
according to General Procedure A using 4-bromo-2-
fluorophenylboronic acid MIDA ester (82.5 mg, 0.25 mmol, 1 
equiv), 2-(cyclohex-1-en-1-yl)-4,4,5,5-tetramethyl-1,3,2-
dioxaborolane (78 mg, 0.375 mmol, 1.5 equiv), 
Pd(dppf)Cl2·DCM (8.2 mg, 0.01 mmol, 4 mol%), K3PO4 (159 
mg, 0.75 mmol, 3 equiv), THF (1 mL, 0.25 M), H2O (22.5 µL, 
1.25 mmol, 5 equiv), and 30% wt. aq. H2O2 (195 µL, 2.5 mmol, 
10 equiv). After 27 h, the reaction mixture was subjected to the 
purification outlined in the General Procedure (silica gel, 0-
10% EtOAc in petroleum ether) to afford the title compound as 
an off-white solid (36 mg, 75%). υmax (film): 3314, 2928, 2859, 
2359, 1593, 1516, 1431, 1290, 1267 cm-1. 1H NMR (CDCl3, 
400 MHz): δ 7.13 (dd, J = 12.5, 2.0 Hz, 1H), 7.08 (ddd, J = 8.0, 
2.0, 1.0 Hz, 1H), 6.99-6.89 (m, 1H), 6.10-6.04 (m, 1H), 5.18 (d, 
J = 3.5 Hz, 1H), 2.41-2.30 (m, 2H), 2.27-2.13 (m, 2H), 1.84-
1.72 (m, 2H), 1.71-1.60 (m, 2H). 13C NMR (CDCl3, 101 MHz): 
δ 150.4 (d, 1JC-F = 237.0 Hz), 141.5 (d, 
2
JC-F = 16.2 Hz), 135.7 
(d, 3JC-F = 8.1 Hz), 134.6 (d, JC-F = 2.7 Hz), 123.7, 120.6 (d, 
3
JC-
F = 5.4 Hz), 116.2, 111.5 (d, 
2
JC-F = 18.8 Hz), 26.9, 25.3, 22.5, 
21.6. 19F NMR (CDCl3, 376 MHz): δ Ð141.4 (s, 1F). HRMS: 
exact mass calculated for [M+H]+ (C12H14FO) requires m/z 
193.1023, found m/z 193.1023. 
3u: (E)-3-(2-Cyclopropylvinyl)phenol. Prepared according to 
General Procedure B using 3-bromophenylboronic acid MIDA 
ester (78 mg, 0.25 mmol, 1 equiv), (E)-2-(2-cyclopropylvinyl)-
4,4,5,5-tetramethyl-1,3,2-dioxaborolane (73 mg, 0.375 mmol, 
1.5 equiv), Pd(OAc)2 (2.3 mg, 0.01 mmol, 4 mol%), SPhos (8.2 
mg, 0.02 mmol, 8 mol%), K3PO4 (159 mg, 0.75 mmol, 3 
equiv), THF (1 mL, 0.25 M), H2O (22.5 µL, 1.25 mmol, 5 
equiv), and 30% wt. aq. H2O2 (195 µL, 2.5 mmol, 10 equiv). 
After 27 h, the reaction mixture was subjected to the 
purification outlined in the General Procedure (silica gel, 0-
15% EtOAc in petroleum ether) to afford the title compound as 
an off-white solid (29 mg, 72%). υmax (film): 3321, 3005, 2359, 
1649, 1607, 1580, 1491, 1449, 1277, 1252, 1229, 1153 cm-1. 1H 
NMR (CDCl3, 400 MHz): δ 7.17 (t, J = 8.0 Hz, 1H), 6.94-6.88 
(m, 1H), 6.77-6.84 (m, 1H), 6.68 (ddd, J = 8.0, 2.5, 1.0 Hz, 
1H), 6.43 (d, J = 15.7 Hz, 1H), 5.73 (dd, J = 15.7, 8.8 Hz, 1H), 
4.99 (s, 1H), 1.64-1.52 (m, 1H), 0.89-0.81 (m, 2H), 0.57-0.49 
(m, 2H). 13C NMR (CDCl3, 101 MHz): δ 155.2, 139.1, 135.1, 
129.2, 126.5, 118.0, 113.1, 111.7, 14.0, 6.8. HRMS: exact mass 
calculated for [M+H]+ (C11H13O) requires m/z 161.0959, found 
m/z 161.0959. 
3v: (E)-2-Styrylphenol. Prepared according to General 
Procedure A using 2-bromophenylboronic acid MIDA ester 
(70.6 mg, 0.226 mmol, 1 equiv), (E)-4,4,5,5-tetramethyl-2-
styryl-1,3,2-dioxaborolane (78.0 mg, 0.339 mmol, 1.5 equiv), 
Pd(dppf)Cl2·DCM (7.4 mg, 0.009 mmol, 4 mol%), K3PO4 (144 
mg, 0.678 mmol, 3 equiv), THF (0.9 mL, 0.25 M), H2O (20 µL, 
1.13 mmol, 5 equiv), and 30% wt. aq. H2O2 (177 µL, 2.26 
mmol, 10 equiv). After 27 h, the reaction mixture was subjected 
to the purification outlined in the General Procedure (silica gel, 
0-30% Et2O in petroleum ether) to afford the title compound as 
a yellow solid (38 mg, 85%). υmax (solid): 3526, 3042, 2927, 
1584, 1497, 1454, 1329 cm-1. 1H NMR (CDCl3, 500 MHz): δ 
7.52-7.57 (m, 3H), 7.35-7.41 (m, 3H), 7.28 (s, 1H), 7.11-7.19 
(m, 2H), 6.97 (dt, J = 7.5, 0.8 Hz, 1H), 6.82 (dd, J = 8.2, 0.9 
Hz, 1H), 4.97 (br. s., 1H). 13C NMR (CDCl3, 126 MHz): δ 
153.0, 137.6, 130.2, 128.7, 127.7, 127.3, 126.6, 124.7, 123.0, 
121.2, 116.0. HRMS: exact mass calculated for [M-H]- 
(C14H11O) requires m/z 195.0815, found m/z 195.0821. 
3w: 4-(3,6-Dihydro-2H-pyran-4-yl)phenol. Prepared according 
to General Procedure A using 4-bromophenylboronic acid 
MIDA ester (70.6 mg, 0.226 mmol, 1 equiv), 2-(3,6-dihydro-
2H-pyran-4-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (71.2 
mg, 0.339 mmol, 1.5 equiv), Pd(dppf)Cl2·DCM (7.4 mg, 0.009 
mmol, 4 mol%), K3PO4 (144 mg, 0.678 mmol, 3 equiv), THF 
(0.9 mL, 0.25 M), H2O (20 µL, 1.13 mmol, 5 equiv), and 30% 
wt. aq. H2O2 (177 µL, 2.26 mmol, 10 equiv). After 27 h, the 
reaction mixture was subjected to the purification outlined in 
the General Procedure (silica gel, 0-30% Et2O in petroleum 
ether) to afford the title compound as a white solid (48 mg, 
93%). υmax (solid): 3271, 2924, 2872, 1610, 1588, 1515, 1442 
cm-1. 1H NMR (CD3CN, 500 MHz): δ 7.30 (d, J = 8.8 Hz, 2H), 
6.91 (br. s., 1H), 6.79 (d, J = 8.8 Hz, 2H), 6.06 (tt, J = 2.9, 1.5 
Hz, 1H), 4.23 (q, J = 2.8 Hz, 2H), 3.86 (t, J = 5.5 Hz, 2H), 
2.47-2.42 (m, 2H). 13C NMR (CD3CN, 126 MHz): δ 156.3, 
133.3, 132.1, 125.8, 120.4, 115.1, 65.4, 64.0, 26.9. HRMS: 
exact mass calculated for [M+H]+ (C11H13O2) requires m/z 
177.0910, found m/z 177.0906. 
7: 2',4'-Difluoro-4-hydroxy-[1,1'-biphenyl]-3-carboxylic acid 
(Diflunisal). To a solution of methyl 2',4'-difluoro-4-hydroxy-
[1,1'-biphenyl]-3-carboxylate (13 mg, 0.049 mmol, 1 equiv) in 
THF (1 mL) and water (1 mL) was added KOH (3 mg, 0.054 
mmol, 1.1 equiv). The reaction was heated to 80 ûC for 3 h 
before being allowed to cool to room temperature and 
concentrated under vacuum. The residue was partitioned 
between EtOAc (10 mL) and 2 M HCl (5 mL) and the aqueous 
extracted with EtOAc (2x10 mL). The combined organics were 
dried through a hydrophobic frit and evaporated to dryness to 
afford the desired product (12 mg, 98%) as a white solid. υmax 
(film): 2961, 2614, 1668, 1618, 1587, 1483, 1449, 1300, 1267, 
1236, 1209 cm-1. 1H NMR (DMSO-d6, 400 MHz): δ 7.94-7.91 
(m, 1H), 7.70-7.67 (m, 1H), 7.59 (td, J = 8.9, 6.6 Hz, 1H), 7.35 
(ddd, J = 11.4, 9.1, 2.5 Hz, 1H), 7.21-7.16 (m, 1H), 7.08 (d, J = 
8.5 Hz, 1H). Exchangeable protons were not observed. 13C 
NMR (DMSO-d6, 101 MHz): δ 171.5, 160.7, 160.1, 161.5 (dd, 
1
JC-F = 250.0 Hz, 
3
JC-F = 11.0 Hz), 159.0 (dd, 
1
JC-F = 250.0 Hz, 
3
JC-F = 11.0 Hz), 135.8, 131.5 (dd, 
3
JC-F = 5.4 Hz, 
3
JC-F = 8.8 
Hz), 130.3, 125.1, 123.7 (dd, 2JC-F = 17.6 Hz, JC-F = 2.7 Hz), 
117.6, 113.2, 112.0 (dd, 2JC-F = 20.5 Hz, JC-F = 2.7 Hz), 104.5 
(dd, 2JC-F = 26.5, 26.5 Hz). 
19F NMR (DMSO-d6, 376 MHz): δ -
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111.40 (d, J = 8.2 Hz, 1F), -114.17 (d, J = 8.2 Hz, 1F). HRMS: 
exact mass calculated for [M-H]- (C13H7F2O3) requires m/z 
249.0369, found m/z 249.0370. 
8: 4'-Hydroxy-[1,1'-biphenyl]-4-carbonitrile. Prepared 
according to General Procedure A using 4-bromophenylboronic 
acid MIDA ester (78 mg, 0.25 mmol, 1 equiv), 2-(4-
cyanophenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (86 mg, 
0.375 mmol, 1.5 equiv), Pd(dppf)Cl2·DCM (8.2 mg, 0.01 
mmol, 4 mol%), K3PO4 (159 mg, 0.75 mmol, 3 equiv), THF (1 
mL, 0.25 M), H2O (22.5 µL, 1.25 mmol, 5 equiv), and 30% wt. 
aq. H2O2 (195 µL, 2.5 mmol, 10 equiv). After 27 h, the reaction 
mixture was subjected to the purification outlined in the 
General Procedure (silica gel, 0-15% Et2O in petroleum ether) 
to afford the desired product as a white solid (39 mg, 80%). 
υmax (film): 3375, 2228, 1601, 1587, 1491, 1204, 1179 cm
-1. 1H 
NMR (DMSO-d6, 400 MHz) δ 9.79 (s, 1H), 7.85 (d, J = 8.5 Hz, 
2H), 7.82 (dd, J = 22.4, 8.7 Hz, 4H), 6.89 (d, J = 8.5 Hz, 2H). 
13C NMR (DMSO-d6, 101 MHz): δ 158.3, 144.6, 132.7, 128.8, 
128.3, 126.5, 119.1, 116.0, 108.7. HRMS: exact mass 
calculated for [M-H]- (C13H8NO) requires m/z 194.0611, found 
m/z 194.0606. 
9: 4-Methoxy-4'-(thiophen-2-yl)-[1,1'-biphenyl]-3-ol. To an 
oven dried 5 mL microwave vial was added 4-
bromophenylboronic acid MIDA ester (78 mg, 0.25 mmol, 1 
equiv), 4,4,5,5-tetramethyl-2-(thiophen-2-yl)-1,3,2-
dioxaborolane (79 mg, 0.375 mmol, 1.5 equiv), 
Pd(dppf)Cl2·DCM (8.2 mg, 0.01 mmol, 4 mol%), and K3PO4 
(159 mg, 1 mmol, 4 equiv). The vial was then capped and 
purged with N2 before addition of THF (1 mL, 0.25 M) and 
H2O (90 µL, 5 mmol, 20 equiv). The reaction mixture was then 
heated to 90 ¡C in a sand bath for 24 h. The reaction mixture 
was allowed to cool to room temperature before adding (5-
bromo-2-methoxyphenyl)boronic acid MIDA ester (85 mg, 
0.25 mmol, 1 equiv). The vial was then recapped and purged 
again with N2 before being heated to 90 ¡C for a further 24 h. 
The reaction mixture was allowed to cool to room temperature 
then decapped, cooled to 0 ûC and 30% wt. aq. H2O2 (195 µL, 
2.5 mmol, 10 equiv) was added dropwise. The reaction mixture 
was then stirred at room temperature for 3 h. The reaction 
mixture was then cooled to 0 ûC and quenched with sodium 
metabisulphite (190 mg, 1 mmol, 4 equiv) before being 
concentrated under vacuum. The residue was then dissolved in 
EtOAc (10 mL) and washed with sat. aq. NH4Cl (2x10 mL) and 
brine (10 mL). The aqueous extracts were extracted with 
EtOAc (10 mL), the combined organics filtered through a 
hydrophobic frit packed with Celite¨ and concentrated under 
vacuum before being purified by column chromatography 
(silica gel, 10-20% Et2O in petroleum ether) to afford the title 
compound as an off-white solid (64 mg, 91%). υmax (film): 
3377, 2980, 1502, 1263, 1219 cm-1. 1H NMR (CDCl3, 500 
MHz): δ 7.55-7.49 (m, 2H), 7.23 (ddd, J = 4.8, 4.3, 1.1 Hz, 
2H), 7.10-7.06 (m, 2H), 6.99 (dd, J = 8.6, 2.4 Hz, 1H), 6.89-
6.85 (m, 2H), 6.74 (d, J = 8.6 Hz, 1H), 5.65 (br. s., 1H), 3.90 (s, 
3H). 13C NMR (CDCl3, 126 MHz): δ 154.6, 146.0, 145.4, 
143.7, 127.4, 127.1, 127.0, 123.4, 122.3, 121.6, 117.4, 115.3, 
112.8, 111.4, 55.6 HRMS: exact mass calculated for [M+H]+ 
(C17H15O2S) requires m/z 283.0787, found m/z 283.0788. 
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